meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic/advanced - colorectal cancer (mCRC)
mCRC - (neo)adjuvant (NA)
mCRC - 1st line (L1)
2
mCRC - 2nd line (L2)
3
endometrial cancer
10
immune chekpoint inhibitors
anti-PD-(L)1
pembrolizumab based treatment
pembrolizumab alone
versus all
vs chemotherapy
vs Standard of Care (SoC)
All patients
Age < 65y (younger)
Age > 75y (older)
Asian type
BRAF mutant
BRAF wild type
ECOG 0
ECOG 1
Gender, female
Gender, male
RAS mutant
RAS wild type
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
button
bars
forest
bayes
pooled
summary
circles
DOR
objective responses (ORR)
progression or deaths (PFS)
AE (any grade)
AE (grade 3-4)
AE leading to death (grade 5)
TRAE (grade 3-4)
TRAE leading to death (grade 5)
Adrenal insufficiency TRAE (grade 3-4)
Alopecia TRAE (grade 3-4)
Anaemia TRAE (grade 3-4)
Arthralgia TRAE (grade 3-4)
Asthenia TRAE (grade 3-4)
Colitis TRAE (grade 3-4)
Decreased appetite TRAE (grade 3-4)
Diabetes TRAE (grade 3-4)
Diarrhoea TRAE (grade 3-4)
Dizziness TRAE (grade 3-4)
Epistaxis TRAE (grade 3-4)
Fatigue TRAE (grade 3-4)
Hepatitis TRAE (grade 3-4)
Hyperthyroidism TRAE (grade 3-4)
Hypophysitis TRAE (grade 3-4)
Hypothyroidism TRAE (grade 3-4)
Increase AST TRAE (grade 3-4)
Increased ALT TRAE (grade 3-4)
Infusion-related reactions TRAE (grade 3-4)
Leucopenia TRAE (grade 3-4)
Mucosal inflammation TRAE (grade 3-4)
Myocarditis TRAE (grade 3-4)
Myositis TRAE (grade 3-4)
Nausea TRAE (grade 3-4)
Nephritis TRAE (grade 3-4)
Neutropenia TRAE (grade 3-4)
Palmar-plantar erythrodysaesthesia syndrome TRAE (grade 3-4)
Pancreatitis TRAE (grade 3-4)
Peripheral neuropathy TRAE (grade 3-4)
Peripheral sensory neuropathy TRAE (grade 3-4)
Pneumonitis TRAE (grade 3-4)
Pruritus TRAE (grade 3-4)
Rash TRAE (grade 3-4)
Severe skin reaction TRAE (grade 3-4)
Stomatitis TRAE (grade 3-4)
Thyroiditis TRAE (grade 3-4)
Vomiting TRAE (grade 3-4)
Abdominal pain AE (grade 3-4)
Alopecia AE (grade 3-4)
Anaemia AE (grade 3-4)
Arthralgia AE (grade 3-4)
Asthenia AE (grade 3-4)
Back pain AE (grade 3-4)
Constipation AE (grade 3-4)
Cough AE (grade 3-4)
Decreased appetite AE (grade 3-4)
Diarrhoea AE (grade 3-4)
Dizziness AE (grade 3-4)
Dry skin AE (grade 3-4)
Dyspepsia AE (grade 3-4)
Dyspnoea AE (grade 3-4)
Epistaxis AE (grade 3-4)
Fatigue AE (grade 3-4)
Headache AE (grade 3-4)
Hypertension AE (grade 3-4)
Hypothyroidism AE (grade 3-4)
Increase AST AE (grade 3-4)
Increased ALT AE (grade 3-4)
Mucosal inflammation AE (grade 3-4)
Nausea AE (grade 3-4)
Neutropenia AE (grade 3-4)
Palmar–plantar erythrodysesthesia syndrome AE (grade 3-4)
Peripheral neuropathy AE (grade 3-4)
Peripheral oedema AE (grade 3-4)
Peripheral sensory neuropathy AE (grade 3-4)
Pruritus AE (grade 3-4)
Pyrexia AE (grade 3-4)
Rash AE (grade 3-4)
Stomatitis AE (grade 3-4)
Vomiting AE (grade 3-4)
Weight decreased AE (grade 3-4)
DOR
mCRC - 1st line (L1)
metastatic/advanced - colorectal cancer (mCRC)
mCRC - 1st line (L1)
versus Standard of Care (SoC)
pembrolizumab alone vs. Standard of Care (SoC)
1
-
×
delta: difference in rate or median (if available)
×
Extraction panel open
An extraction panel is open